454 Life Sciences Corporation, a pioneering entity in the biotechnology sector, is headquartered in the United States. Founded in 2000, the company has made significant strides in the field of next-generation sequencing (NGS), revolutionising genomic research and diagnostics. With a focus on providing advanced sequencing solutions, 454 Life Sciences offers unique products that enable researchers to conduct high-throughput DNA sequencing with unparalleled accuracy and speed. Their innovative technologies have positioned them as a leader in the genomics industry, catering to a diverse clientele that includes academic institutions, pharmaceutical companies, and clinical laboratories. Notable achievements include the development of the 454 Sequencing System, which has set benchmarks for efficiency in genomic analysis. As a key player in the NGS market, 454 Life Sciences continues to drive advancements in personalised medicine and genomic research, solidifying its reputation as a trusted partner in the life sciences community.
How does 454 Life Sciences Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
454 Life Sciences Corporation's score of 83 is higher than 91% of the industry. This can give you a sense of how well the company is doing compared to its peers.
454 Life Sciences Corporation, headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Roche Holding AG, which influences its climate commitments and emissions reporting. As part of its corporate family relationship, 454 Life Sciences Corporation inherits emissions data and climate initiatives from Roche Holding AG. This includes commitments to the Science Based Targets initiative (SBTi) and participation in the Carbon Disclosure Project (CDP), both of which are aimed at reducing greenhouse gas emissions across their operations. While specific reduction targets for 454 Life Sciences Corporation are not detailed, the overarching goals set by Roche Holding AG reflect a commitment to sustainability and climate action. The company is actively engaged in initiatives to enhance its environmental performance, although no specific figures or targets have been disclosed at this time. In summary, while 454 Life Sciences Corporation does not present its own emissions data or reduction targets, it aligns with the climate strategies and commitments of its parent company, Roche Holding AG, to drive progress in reducing carbon emissions and addressing climate change.
Access structured emissions data, company-specific emission factors, and source documents
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 403,136,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 
| Scope 2 | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 
| Scope 3 | 188,924,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 
454 Life Sciences Corporation's Scope 3 emissions, which decreased by 8% last year and increased significantly since 2013, demonstrating supply chain emissions tracking. Nearly all of their carbon footprint comes from suppliers and value chain emissions, representing nearly all emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 71% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
454 Life Sciences Corporation has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.